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To determine whether B-cell presence in brainstem and white matter (WM) lesions is asso-
ciated with poorer pathological and clinical characteristics in advanced MS autopsy cases.
Methods
Autopsy tissue of 140 MS and 24 control cases and biopsy tissue of 24 patients with MS were
examined for CD20+ B cells and CD138+ plasma cells. The presence of these cells was
compared with pathological and clinical characteristics. In corresponding CSF and plasma,
immunoglobulin (Ig) G ratio and oligoclonal band (OCB) patterns were determined. In a
clinical cohort of 73 patients, the presence of OCBs was determined during follow-up and
compared to status at diagnosis.
Results
In 34% of active and 71% of mixed active/inactive lesions, B cells were absent, which correlated
with less pronounced meningeal B-cell infiltration (p < 0.0001). The absence of B cells and
plasma cells in brainstem and WM lesions was associated with a longer disease duration (p =
0.001), less frequent secondary progressive MS compared with relapsing and primary pro-
gressive MS (p < 0.0001 and p = 0.046, respectively), a lower proportion of mixed active/
inactive lesions (p = 0.01), and less often perivascular T-cell clustering (p < 0.0001). Moreover,
a lower CSF IgG ratio (p = 0.006) and more frequent absence of OCBs (p < 0.0001) were
noted. In a clinical cohort, numbers of patients without OCBs in CSF were increased at follow-
up (27.4%).
Conclusions
The absence of B cells is associated with a favorable clinical and pathological profile. This
finding may reflect extremes of a continuum of genetic or environmental constitution, but also a
regression of WM humoral immunopathology in the natural course of advanced MS.
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MS is a heterogeneous disease differing in clinical disease
course,1 radiologic appearance of lesions,2 and response to
immunomodulatory therapies.3 Of interest, variability be-
tween patients with MS is observed in the involvement of
humoral immunity in the disease. At the time of diagnosis,
10% of patients with MS show the absence of oligoclonal
bands (OCBs) consisting of intrathecally produced immu-
noglobulin (Ig) Gs.4 The absence of OCBs is associated with a
decreased number of lesions on MRI and a more benign
disease course.4,5 Furthermore, the presence of OCBs in pa-
tients with clinically isolated syndrome is associated with an
increased risk for clinically definite MS and with an increased
risk of disability progression.6,7
In contrast to its limited presence in early MS,8 advanced
progressive MS is characterized by extensive cortical de-
myelination.9 Active cortical demyelination is observed in
conjunction with the presence of meningeal follicle-like in-
flammatory structures.10–12 The distinct zones of B cells,
plasma cells, and T cells resemble tertiary lymphoid
structures.12,13 The presence of these follicle-like structures
associates with more severe disease, reflected by an earlier
disease onset and faster accumulation of disability and earlier
death.11,12 Recently, Reali et al.14 reported that the density of
meningeal B cells in MS spinal cords correlates with extensive
axonal loss and white matter (WM) lesion area, but also with
density of B cells in the WM perivascular space.
Besides cortical demyelination, demyelinating WM lesions
also add up to disease severity in donors with advanced MS.
In MS autopsy cases, the presence of active and mixed
active/inactive lesions has been reported to be substantial
and correlate with a short time to reaching expanded dis-
ability status scale (EDSS) end points, a shorter time to
death, an unfavorable profile of risk factors for adverse
outcomes, and an unfavorable profile of genetic risk factors
for adverse outcomes.15,16 Furthermore, we showed these
active lesions to be populated by infiltrating T cells with a
dominant tissue-resident memory T (TRM)-cell fraction
showing signs of recent reactivation.17,18 Frischer et al.19
quantified the presence of B cells in MS WM lesions and
found these to be predominantly present in perivascular
cuffs and meninges and less frequently in the parenchyma.
The presence of B cells was found most frequently in acute
lesions in relapsing-remitting (RR) donors and less fre-
quently in progressive patients.19 IgG-producing cells and
IgG deposits are regularly found in MS WM lesions.20,21
Furthermore, the number of B cells reported in late MS
autopsy lesions is highly variable between cases.19,22
The correlation of B-cell presence in WM lesions with clinical
end points and risk factors as well as with meningeal B-cell
infiltration has been limitedly explored. Here, we investigated
the clinical and pathological characteristics of Netherlands
Brain Bank (NBB)MS autopsy cases in association with B-cell
infiltration of brainstem and subcortical WM lesions.
Methods
Donor and Sample Characteristics
One hundred forty-one MS brain donors and 24 non-
neurologic controls from the NBB autopsy cohort
(Amsterdam, The Netherlands) were included for this
analysis of B cells and plasma cells. Donors came to autopsy
between 1991 and 2015 and were diagnosed with MS
according to the contemporary diagnostic criteria by their
treating physicians. Clinical files were collected post-
mortem by the NBB. By retrospective chart analysis, the
clinical diagnosis of MS was confirmed for all patients, and
the clinical course was defined as either RR, secondary
progressive (SP), or primary progressive (PP) by a neu-
rologist.15 No MRI data were available. None of the donors
received MS disease-modifying therapies in the year before
autopsy, except for 1 (B cell–positive) donor on fingolimod.
Detailed donor and tissue characteristics are described in
supplementary table 1, links.lww.com/NXI/A399, and treat-
ment status is provided in supplementary table 2, links.lww.
com/NXI/A399. The pathological diagnosis of MS was con-
firmed for all cases by a certified neuropathologist.15 All donors
were analyzed for anti–myelin oligodendrocyte glycoprotein
(MOG) and anti–aquaporin-4 antibodies using cell-based as-
says (figure e-1, links.lww.com/NXI/A399).23–25
For the immunohistochemical part of this study, 3 types of
tissues were analyzed for the presence of B cells and plasma cells:
(1) standardly dissected tissue blocks at the level of the medulla
oblongata (MO) from 140 MS autopsy cases, (2) subcortical
WM lesions from 73/140 MS autopsy cases (158 WM lesions
with a median 2 lesions per donor for both the donors with and
without B cells) and 24 non-neurologic control donors, and (3)
earlyMS biopsyWM lesions (N= 28) from 24 patients withMS
to explore how findings in postmortem autopsy samples of do-
nors with advanced MS correlate with findings at the earliest
stages ofMS. These sections weremade available by the Institute
for Neuropathology, University Hospital Münster (Münster,
Germany). Additional information on the analysis and selection
of the different tissue samples is described in the supplementary
methods, links.lww.com/NXI/A399.
Glossary
GM = gray matter; IgG = immunoglobulin G;MO =medulla oblongata;MOG =myelin oligodendrocyte glycoprotein;NBB =
Netherlands Brain Bank; OCB = oligoclonal band; PP = primary progressive; RR = relapsing-remitting; SP = secondary
progressive; TRM = tissue-resident memory T (cells); WM = white matter.
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A CSF sample was acquired with a lumbar puncture from 73
patients with MS with an average disease duration of 11.7 ±
8.5 (mean ± SD) years. These patients visited the MS Center
Amsterdam (Amsterdam, The Netherlands) for analysis of
cognitive complaints, which is a common symptom in MS.26
Information on OCB pattern at the time of diagnosis was
collected by a retrospective chart analysis. Patients’ charac-
teristics are provided in table 1.
Standard Protocol Approvals, Registrations,
and Patient Consents
Informed consent was given by the donors of the NBB for
brain autopsy and for the use of material and clinical data for
research purposes. NBB autopsy procedures have been ap-
proved by the medical ethics committee of Amsterdam
UMC, location VUmc, Amsterdam, The Netherlands.
Sampling of biopsies and CSF has been approved by the
medical ethics committee of the University Hospital
Münster and Amsterdam UMC, location VUmc,
respectively.
Immunohistochemistry
Immunohistochemistry of the autopsy tissue samples was
performed on 8-μm-thick formalin-fixed paraffin-embedded
tissue sections. All brainstem and subcortical WM tissue
sections were immunostained for myelin (proteolipid pro-
tein) and HLA (HLA-DR/DQ, referred to as HLA) as pre-
viously described.15,16 Lesions were annotated, and sections
were stained for CD20, CD138,27 and CD3 as described in
the supplementary methods, links.lww.com/NXI/A399. For
CD138, an image of the positive control in tonsil is provided
in figure e-2, links.lww.com/NXI/A399.


















11.7 ± 8.5 49 DMT
51 none






11.4 ± 8.5 53 DMT
47 none
OCB-negative 20 (27.4) 51.5 ± 10.7 14F/6M RR 55
SP 20
Various 25
13.2 ± 8.7 40 DMT
60 none
All OCB-negative
At diagnosis OCB-positive 6 (30) 49.5 ± 9.7 5F/1M BD 17
RR 67
SP 17
11.0 ± 7.0 83 DMT
17 none
Previously elevated IgG, OCB
unknown
4 (20) 60.0 ± 9.6 2F/2M CIS 25
RR 50
SP 25
17.3 ± 5.7 25 DMT
75 none
At diagnosis OCB-negative 4 (20) 49.0 ± 10.6 3F/1M CIS 50
RR 50
6.0 ± 9.4 25 DMT
75 none
Not reported 6 (30) 49.5 ± 12.1 4F/2M RR 50
SP 33
NR 17
16.0 ± 10.1 17 DMT
83 none
OCB-negative, at diagnosis positive
Case 1 56 F RR 20 GLA
Case 2 54 F RR 8 DMF
Case 3 37 F RR 13 DMF
Case 4 52 F BD 4 IFNβ
Case 5 38 F RR 2 DMF
Case 6 60 M SP 16 None
Abbreviations: BD = Balo disease; CIS = clinically isolated syndrome; DMF = dimethyl fumarate; GLA = glatiramer acetate; IFNβ = interferon-β; IgG =
immunoglobulin G; NR = not reported; OCB = oligoclonal band; PP = primary progressive; RR = relapsing-remitting; SP = secondary progressive; various = BD,
CIS, and NR.
Provided is the mean ± SD.
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OCB and IgG Measurement in CSF and Plasma
A selection of 16 NBB MS cases without the presence of
B cells and CD138+ plasma cells in the perivascular space and
parenchyma of both MO and subcortical active WM lesions
and 16MS cases with B cells and CD138+ plasma cells at these
locations was made to analyze postmortemCSF samples. One
case was excluded due to CSF anti-MOG positivity (figure
e-1, links.lww.com/NXI/A399). Paired plasma samples were
available from 20 of these MS autopsy cases (10 with B cells
and 10 without B cells). In addition, paired CSF and serum
samples of 73 patients with MS were analyzed. In all samples,
IgG levels were determined with nephelometry, and the
presence of OCBs was analyzed with isoelectric focusing
followed by IgG immunoblotting.28
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 8
(8.1.1, April 2019; GraphPad, San Diego, CA, USA). Pro-
portional differences between 2 or more strata were tested
with the Fisher exact and χ2 tests, respectively. Brainstem
lesion load and reactive site load were log transformed.
Normally distributed data were analyzed using a Student t
test. A nonparametric Mann-Whitney U test was used when
data were not normally distributed data. For disease duration
and age at death a survival, analysis was performed using the
Gehan-Breslow-Wilcoxon test.
Data Availability
The data that support the findings of this study are available
from the corresponding author on reasonable request.
Results
B Cells Are Present in Early MS Biopsy Lesions
and in Active and Mixed Active/Inactive MS
Autopsy Lesions
Of the NBBMS autopsy cohort, we analyzed thematerial of N
= 140 donors for the current study. First, we analyzed the
presence of B cells and CD138+ plasma cells in the MO
because this is one of the few standardly dissected regions in
the NBB MS autopsy protocol, which contains both the WM
and gray matter (GM) brain parenchyma and the meninges.
B cells were more often present in the perivascular space (p =
0.004) and meninges (p < 0.0001) compared with the brain
parenchyma (17%, 51%, and 4% of cases, respectively; figure
1, A and B). In the MO collection, 85 sections contained MS
lesions, and 53 sections did not contain MS lesions. B cells
and CD138+ plasma cells were found more frequently (p =
0.028 and p = 0.038, respectively) in sections with MS lesions
(21% had B cells and 19% had plasma cells) compared with
normal-appearingMO tissue sections (9% had B cells, and 8%
had plasma cells) (figure 1, C and D).
To investigate the association with WM lesion characteristics,
we scored the presence of B cells and CD138+ plasma cells in
subcortical WM from 24 non-neurologic controls and 73 MS
autopsy cases, containing 158 MS lesions (10 reactive, 41
active, 66 mixed active/inactive, 25 inactive, and 16 remyeli-
nated). Moreover, we determined the presence of B cells and
CD138+ plasma cells in 28 early MS biopsies from WM le-
sions, which were all active. In the non-neurologic controls,
we identified B cells (2–5 cells per section) in the meninges in
4% (2 of 24) of the cases. B cells were more frequently found
in early biopsy (93%; p < 0.0001) and in active (66%; p <
0.0001) and mixed active/inactive (29%; p < 0.0001) autopsy
MS lesions compared with control WM. Notably, in 34% of
the active autopsy lesions, no B cells were identified. In re-
active (10%), inactive (8%), and remyelinated lesions (6%),
B cells were not significantly enriched compared with control
WM (figure 1E). In control WM and meninges, no CD138+
plasma cells were identified. CD138+ plasma cells were found
in early biopsy lesions (56%; p = 0.004) and in all autopsy MS
lesion subtypes—reactive (10%; p = 0.002), active (22%; p <
0.0001), mixed active/inactive (8%; p = 0.007), inactive
(24%; p < 0.0001), and remyelinated (19%; p < 0.0001)
compared with control WM (figure 1, F–I).
The Presence of B Cells and CD138+ Plasma
Cells Is a General Donor Characteristic
We next assessed the presence of B cells and CD138+ plasma
cells within multiple locations (parenchyma, perivascular
space, and meninges) and tissue blocks (MO and subcortical
WM) from the same donors (figure 2, A and B). The presence
of B cells in the perivascular space was associated with the
presence of B cells in the meninges (92% and 43% in donors
with and without perivascular B cells, respectively; p < 0.0001;
figure 2D). This is in accordance with Reali et al.,14 who also
observed an increased number of B cells in meninges to be
associated with an increased number of B cells in perivascular
space of MS spinal cords. Furthermore, the presence of B cells
in the MO was associated with the presence of B cells in the
subcortical WM (50% and 27% in donors with and without
MO B cells, respectively; p = 0.001; figure 2E).
Limited Presence of B Cells in MS Autopsy
Cases Associates With a Favorable Clinical and
Pathological Profile
To assess whether the presence of B and CD138+ plasma cells
in MO and subcortical WM lesions correlates with more se-
vere MS, likewise earlier reported for meningeal B-cell infil-
trates, we compared donors with and without B cells at these
locations. B cells were frequently encountered in perivascular
clusters with T cells (figure 3A). Cases without B cells at the
MO showed less often perivascular cuffing of T cells in the
MO (11% and 35%; p < 0.0001, figure 3B). Cases without
B cells in subcortical WM showed a trend for a lower number
of T cells in subcortical MS lesions (median 3.3 vs 8.3 cells/
mm2; p = 0.06; figure 3C) and a lower overall percentage of
mixed active/inactive lesions (mean 23.7% vs 39.6%; p = 0.01;
figure 3D) compared with MS donors with B cells. Clinically,
they showed a higher age at death (median 69.0 vs 55.5; p =
0.0006; figure 3E) and a less severe clinical disease course,
defined as a longer disease duration (median 31.0 vs 22.0; p =
4 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 2 | March 2021 Neurology.org/NN
0.007; figure 3F), and they more often had a persistent re-
lapsing or PP course compared with an SP course (100% and
87% vs 75%; p < 0.0001 and p = 0.046; figure 3G). There was
no difference in brainstem lesion load, reactive site load,
percentage of inactive remyelinated areas, and incidence of
cortical GM lesions between MS cases with and without
B cells at the investigated locations (figure e-3, links.lww.
com/NXI/A399).
Figure 1 B Cells Are Enriched in Biopsy Lesions and Active and Mixed Active/Inactive Lesions at Autopsy
(A/B) B cells and plasma cells were enriched in the perivascular space and meninges of the MO compared with the MO parenchyma. (C/D) MO lesions
contained more frequently B cells and plasma cells compared with the normal-appearing medulla oblongata (NA MO). MS lesion subtypes were analyzed in
the subcortical WM. (E) Early MS biopsy lesions significantly more often contained B cells compared with all autopsy lesions. In active and mixed active/
inactive autopsy lesions, B cells were significantly more often present compared with control WM. (F) Early MS biopsy lesions significantly more often
contained plasma cells compared with autopsy lesions. Plasma cells were significantly more often present in all MS lesion types compared with control WM.
(G) Example of an inflammatory active MS lesions of a secondary progressive MS brain donor with MS for 27 years, stained for HLA (black) and proteolipid
protein (brown). Scale bar is 500 μm. (H/I) In the perivascular space, B cells (CD20+, panel H, scale bar is 50 μm) and a plasma cell (CD138+, panel I, scale bar is
25 μm) were present (both brown color). *p < 0.05, **p < 0.01, and ****p < 0.0001. WM = white matter
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MS Autopsy Cases With Limited Presence of
B Cells Show a Lower Intrathecal IgG
Production and Lack More Often OCBs
Because our data suggest an association between the
presence of B cells in meninges and MO/subcortical WM,
as well as an association with a more severe pathological
and clinical profile, we explored its relevance for intrathecal
B-cell activation. Because an increased intrathecal IgG
production and OCB presence are highly correlating bio-
markers of MS,29 and the presence of OCB’s is associated
with adverse outcomes,6,30 we explored whether these CSF
biomarkers were associated with B-cell and CD138+
plasma-cell presence in MO and subcortical WM lesions.
We conducted an extreme-of-outcome analysis by selecting
16 cases with B cells and 16 cases without B cells and
CD138+ plasma cells in both MO and subcortical WM
lesions. One MS case with B cells and CD138+ plasma cells
was excluded before OCB analysis because anti-MOG an-
tibodies were detected in the postmortem CSF. There was
no significant association of IgG index and OCB presence
(figure 4A) with postmortem delay. The pH of postmortem
CSF showed a positive correlation with IgG index
(Spearman correlation R = 0.498; p = 0.035), but not with
OCB presence or presence of B cells (figure e-4, links.lww.
com/NXI/A399). Selected cases lacking B cells and
CD138+ plasma cells in MO and subcortical WM lesions
showed a lower CSF IgG level (median 0.04 vs 0.07; p =
0.02, figure 4B) and a lower IgG CSF/plasma ratio (median
0.003 vs 0.008; p = 0.007, figure 4C), indicating a lower
intrathecal IgG production compared with MS cases with
B cells. CSF OCBs were absent in 37% of cases without
B cells and CD138+ plasma cells, whereas all cases with
Figure 2 B-Cell and Plasma Cell Presence in the Meninges and Perivascular Space Is Consistent Within Donors
(A) In the MO of donor 1 with 27 years
of secondary progressive MS, B-cell
and plasma cell infiltrates were iden-
tified in both the perivascular space
(PVS) and themeninges (M). Scale bars
are 100 μm for CD20 and 50 μm for
CD138. (B) In the MO of donor 2 with a
primary progressive disease course
and a disease duration of 2 years, B
cells were detected in the perivascular
space but not in themeninges, and no
plasma cells were identified. Scale
bars are 50 μm for CD20 and CD138 in
the PVS and 100 μm for CD20 in the
meninges. (C) In the MO of donor 3
with a relapsing disease course for 38
years, no B cells or plasma cells were
identified in both the meninges and
the perivascular space. Scale bars are
as in A. (D) The absence of B cells in the
perivascular space (PVS) is associated
with the absence of B cells in the me-
ninges. (E) The absence of B cells in the
MO is associatedwith the absence of B
cells in the subcortical white matter.
**p < 0.01 and ****p < 0.0001. MO =
medulla oblongata
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B cells displayed CSF OCBs (p < 0.0001; figure 4D). This
observation suggests that these MS cases with limited
presence of B cells and CD138+ plasma cells in MO and
subcortical WM lesions are characterized by an overall al-
tered CSF IgG clonality and lower IgG production. This
observation is again in line with the strong correlation
reported by Reali et al.14 between meningeal and peri-
vascular B-cell presence. In addition, the IgG index, but not
the presence of OCBs, was positively correlated with the
number of T cells in subcortical WM (figure e-5A, links.
lww.com/NXI/A399). Other pathological end points did
not correlate with IgG production or clonality (figure e-
5B–D, links.lww.com/NXI/A399).
OCBs Can Disappear Over Time in Patients
With MS
In MS autopsy cases selected for absence of B cells and CD138+
plasma cells, the prevalence of OCBs was lower than the
expected 90%OCB positivity of patients withMS at diagnosis.31
This difference could be explained by selection of MS donors
with an extreme profile of genetic or environmental factors,16 but
also by a decline of the intrathecal humoral immune response
over time in chronic MS. In our current study, 2 of 6 MS cases
without OCBs at autopsy had an elevated IgG ratio at diagnosis
without information on OCBs, 1 of 6 donors had normal di-
agnostic CSF examination, and no information was available for
the 3 other donors. To explore whether a dynamic course of
Figure 3 MS Cases With Limited Presence of B Cells Show a Favorable pathological and Clinical Profile
(A) B cells were often encountered in
perivascular clusters together with
T cells. Scale bars are 100 μm. (B) MS
cases with the limited presence of B
cells showed less often perivascular
clustering of CD3+ T cells, (C) a lower
number of CD3+ T cells in MS lesions,
(D) a lower percentage of mixed ac-
tive/inactive (mA/I) lesions, (E) a higher
age at death, (F) a longer disease du-
ration, and (G)more often a secondary
progressive disease course. *p < 0.05
and ****p < 0.0001.
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OCB pattern throughout the disease course of MS can be a
plausible explanation of our findings, the presence of OCBs was
determined in a clinical cohort of 73 patients with MS who
underwent a lumbar puncture after an average disease duration
of 11.7 ± 8.5 (mean ± SD) years. In 27.4% (20 of 73) of the
patients withMS,OCBs were absent. In 6 of the 20 patients with
MS without OCBs at follow-up, OCBs were present at the time
of diagnosis (table 1). Although laboratory differences can be
confounders, these data support the hypothesis that the contri-
bution of B cells toMS pathology may decline during the course
of MS.
Discussion
We here demonstrate the absence of B cells and CD138+
plasma cells in 34% of the active WM lesions of advanced
MS cases in the NBB autopsy cohort. Cases without B cells
at the MO or subcortical WM showed a more favorable
pathological profile as indicated by a lower number of
T cells in MS lesions, a lesser frequency of perivascular
cuffing of T cells, and a lower percentage of mixed active/
inactive lesions. Clinically, they manifested with a less fre-
quent SP disease course, a longer disease duration, and a
lower percentage of mixed active/inactive lesions compared
with the MS donors with B cells in MO or subcortical WM
lesions. Furthermore, a selected subgroup of patients with
MS without WM B cells and CD138+ plasma cells had a
lower intrathecal IgG production and lacked more often
unique OCBs in postmortem CSF. Our findings indicate
that besides an important role of meningeal B cells in cor-
tical pathology of advanced progressive MS, B-cell in-
filtration in WM is also a detrimental phenomenon at the
later stages of MS.
Figure 4 MS Cases With Limited B Cells Show Lower Intrathecal IgG Production and More Often Lack OCBs
(A) Example of OCB patterns in paired
CSF and plasma for a donor without
(donor 1) and a donor with (donor 2)
CSF-unique OCBs. MS cases with lim-
ited presence of B cells showed (B) a
lower concentration of IgG in post-
mortem CSF and (C) a lower CSF/
plasma IgG ratio, suggesting a lower
intrathecal IgG production, and (D)
more often lacked CSF OCBs. *p < 0.05,
**p < 0.01, and ****p < 0.0001. IgG =
immunoglobulin G; OCB = oligoclonal
band.
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In MS and also other autoimmune diseases, B cells have been
described to play an important role in antigen presentation
and cytokine production, which induces the activation and
proliferation of T cells.32–35 MS cases with B cells show an
increased number of T cells in their MS lesions suggesting
increased T-cell activation. We and others previously showed
that reactivated TRM cells are associated with the ongoing
inflammatory lesion activity in WM lesions from advanced
MS cases.19,22,36 InMS lesions, these reactivated TRM cells are
often encountered in clusters in the perivascular space to-
gether with B cells,17,37 suggesting that antigen presentation
and reactivation of TRM cells induced by B cells potentially
occur at this location.17,18,38 This illustrates that besides IgG
production, B cells may have different functional roles in MS
WM lesions.
We show that CD138+ plasma cells are present more often in
MS lesions compared with control and normal-appearing
WM in line with earlier reports, however, only in a low per-
centage of the MS autopsy cases.20,21 Of interest, CD138+
plasma cells were most often present in inactive lesions
compared with the other lesion subtypes. Prineas et al.21
previously showed in a detailed electron microscopy study of
the perivascular space in MS tissues that high numbers of
plasma cells are present in inactive lesion areas. This suggests
that CD138+ plasma cells play a less prominent role compared
with B cells in the ongoing microglial activity of MS lesions.
Ocrelizumab and rituximab, which show an effect on disease
progression in MS, are directed against circulating CD20+
B cells but do not affect CD138+ plasma cells.
A large heterogeneity in the number of B cells and the pres-
ence of IgG depositions inMS lesions has been described over
the past decades. In both early MS biopsies and late MS
autopsies, the presence39–41 and absence39,42 of IgG deposits
inMS lesions have been described. Also, the number of B cells
in MS autopsy lesions is highly heterogenous between MS
cases. In 34% of the inflammatory active MS lesions in au-
topsy tissue, we identified no B cells, and we showed that the
presence of B cells correlates between different location (MO
and subcortical WM) and compartments (parenchyma, per-
ivascular space, and meninges) in an individual donor.
In a selected subgroup of MS cases without WM B cells, a
lower intrathecal IgG production and a more frequent ab-
sence of OCBs were found. The presence of OCBs in 60% in
these MS cases is lower compared with clinical MS cohorts,
where 90% showed OCBs at diagnosis.4 Possibly, we now
selected an extreme subgroup of MS cases with a genetic
profile at one side of a continuum that restricts involvement
of B cells in MS lesion pathogenesis.16 Alternatively, because
we identified B cells in 92% of the early MS biopsy lesions,
and the MS cases with limited B-cell presence in autopsy
tissue had a longer disease duration and older age, B-cell
involvement in WM lesion activity might be extinguishing
over time. Accordingly, Frischer et al.19 reported higher
numbers of perivascular B cells in donors with relapsing and
progressive disease compared with inactive disease. We
provided some support for this hypothesis, by observing in a
clinical cohort the absence of OCBs in 27.4% of patients
after a disease duration of 11.7 ± 8.5 (mean ± SD) years. In 6
of these patients without OCBs, their presence at diagnosis
could be validated. In 4 of these patients, the elevated IgG
index at diagnosis was validated. These data require careful
interpretation because comparison with historical data on
OCB presence may be inaccurate. It is not likely that treat-
ment with disease-modifying therapies confounds these re-
sults. In clinical studies, the presence of CSF OCBs was not
affected by highly efficacious therapies as fingolimod,43 rit-
uximab,44 and alemtuzumab,45 whereas treatment with
natalizumab46,47 and cladribine48 was associated with re-
duced OCBs. Treatment with dimethyl fumarate has not
been associated with lower CSF IgG production.49 Although
loss of CSF OCBs has been described in a cohort of in-
terferon-beta– and glatiramer acetate–treated patients with
MS,50 this has not been observed in controlled studies.
Whether the absence of perivascular B cells truly is a bio-
marker for the regression of WM inflammatory disease ac-
tivity in advanced MS remains to be determined. Regarding
cessation of disease-modifying therapies in advanced MS,
this could be a clinically useful hypothesis to pursue.
Our study has some limitations. Because of the structure of
the NBB MS tissue dissection protocol, we could only in-
vestigate the presence of B cells at selected locations in WM
and meninges. Bias in our data by sample and site selection
cannot be excluded, which may be partially overcome by
selecting a standardly dissected location and comparing
multiple locations within the same donor. The extreme out-
come analysis, comparing donors with or without B cells at
multiple locations in a dichotomous approach, provides a
rather crude estimate of biological associations than correla-
tion analyses. However, due to limited availability of material,
this was for the current research question in this cohort the
most feasible approach.
In sum, we here demonstrate in an advanced MS autopsy
cohort that the absence of B cells at the MO and subcortical
WM is associated with a favorable clinical and pathological
profile. This finding may reflect extremes of a continuum of
genetic or environmental constitution but also a regression of
WM humoral immunopathology in the natural course of ad-
vanced MS.
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22. Machado-Santos J, Saji E, Tröscher AR, et al. The compartmentalized inflammatory
response in the multiple sclerosis brain is composed of tissue-resident CD8+
T lymphocytes and B cells. Brain 2018;141:2066–2082.
23. Waters PJ, Komorowski L,Woodhall M, et al. Amulticenter comparison ofMOG-IgG













content; major role in the
acquisition of data; study
concept or design; and













content; major role in the
acquisition of data; and










content; major role in the
acquisition of data; and











content; major role in the
acquisition of data; and












































content; study concept or















content; study concept or
design; and analysis or
interpretation of data
10 Neurology: Neuroimmunology & Neuroinflammation | Volume 8, Number 2 | March 2021 Neurology.org/NN
24. Waters P, Reindl M, Saiz A, et al Multicentre comparison of a diagnostic assay:
aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2016;
87:1005–1015.
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